Lecetam Oral Solution Special Precautions

Antiepileptics are associated with an increased risk of suicidal behavior/thoughts with use (regardless of use); patients should be monitored for signs/symptoms of depression, suicidal tendencies, and other unusual behavior changes during therapy.
Psychosis, hallucination, and behavioral symptoms (including aggression, anger, anxiety, depersonalization, depression, and personality disorder) may occur; incidence may be increased in children. Dose reduction may be required.
Levetiracetam should be withdrawn gradually, when possible, to minimize the potential of increased seizure frequency.
Use caution with renal impairment; dosage adjustment may be necessary.
May cause CNS depression (weakness, dizziness, and somnolence) during the first month of therapy.
Decreases in red blood cell counts, haemoglobin, haematocrit, white blood cell counts and neutrophil have been observed. Case of eosinophilia, agranulocytosis, and lymphocytosis have also been reported.
Efficacy and safety of this drug in children < 4 years (oral) or < 16 years (intravenous) have not been established.